SFA Therapeutics Strengthens Management Team with Appointment of Chief Medical Officer
JENKINTOWN, Pa., May 2, 2024 /PRNewswire/ -- SFA Therapeutics, Inc., a clinical-stage biopharmaceutical company developing oral small-molecule biosynthetic compounds for the treatment of inflammatory diseases, today announced the appointment of Stefan C. Weiss, MD, MBA, as Chief Medical Officer.
- JENKINTOWN, Pa., May 2, 2024 /PRNewswire/ -- SFA Therapeutics, Inc., a clinical-stage biopharmaceutical company developing oral small-molecule biosynthetic compounds for the treatment of inflammatory diseases, today announced the appointment of Stefan C. Weiss, MD, MBA, as Chief Medical Officer.
- "Dr. Weiss brings decades of multi-faceted clinical and industry experience in both dermatology and immunology," commented Ira Spector, Ph.D., CEO of SFA Therapeutics.
- "I am honored to join the SFA Therapeutics team to help shape the clinical pathway forward for SFA-002 and other candidates that target inflammatory disease.
- As a practicing dermatologist, I have witnessed the immense need for novel therapeutics with greater efficacy and fewer side effects than the currently available treatments for chronic inflammatory skin conditions," stated Dr. Weiss, Chief Medical Officer of SFA Therapeutics.